Pneumonia is an infection of one or both lungsthat is usually caused by bacteria, viruses, fungi, or parasites. There are many different manifestations of pneumonias based on the type of microbe causing it. In some cases, a microbe can cause different kinds of pneumonia. Sometimes pneumonia af...
[1]Platt Andrew, et al.185: PREVALENCE OF BACTERIAL AND FUNGAL COINFECTIONS IN A COVID-19 AUTOPSY CASE SERIES.#SCCM2022 [2]Singh Vishal, et al.215: A RARE INFECTION FOLLOWING COVID-19 PNEUMONIA TREATMENT.#SCCM2022 [3]Rivosecchi Ryan, et al.201: HIGH RATES OF INVASIVE FUNGAL INFECTION ...
Yet, COVID-19 pneumonia [2], despite falling in most of the circumstances under the Berlin definition of ARDS [3], is a specific disease, whose distinctive features are severe hypoxemia often associated with near normal respiratory system compliance (more than 50% of the 150 patients measured ...
非重症和危重症COVID-19的本质特征是病毒性肺炎,危重症COVID-19最常合并的肺部并发症是ARDS。基于ARDS目前的临床定义,它可能的病理基础是多样化的,包括弥漫性肺泡损伤(diffusing alveolar damage, DAD)、急性纤维素性机化性肺炎(acute fibrosing organizing pneumonia, AFOP)、机化性肺炎( organizing pneumonia , OP)等...
美国首例COVID-19病例于2020年1月20日在华盛顿州确诊后,美国本土COVID-19患者数量持续激增,到目前确诊超过两千五百万,死亡病例高达四十多万。FDA在批准药物使用中有极为严格的审批流程,但COVID-19的大流行毫无疑问迫使其加快推进新的治疗手段的紧急使用。
14.Guo D, Pan S, Wang M, Guo Y.Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports.Undersea Hyperb Med 2020 SecondQuarter;47(2):181–187. 15.HBO2 for COVID-19: cl...
Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with ...
1.Wuhan Municipal Health Commission.Report of Clustering Pneumonia of Unknown Etiology in Wuhan City.Wuhan; 2019.Available online:wjw.wuhan.gov.cn (accessed on 18 June 2020). 2.World Health Organization.General’s Opening Remarks at the Media Brie...
近期,我国多地Covid-19病例数急剧升高。尽管大部分患者仅有上呼吸道感染无需住院治疗,但少数罹患基础疾病或有其他高危因素的Covid-19患者仍会进展为重症甚至死亡(见图1)。 我们根据NEJM、《NEJM期刊荟萃》和美国国立卫生研究院(NIH)的相关内容,为读者梳理了重症Covid-19的高危因素和治疗策略,供临床医生参考。
convalescent plasma(COVID-19恢复期血浆)、Bamlanivimab(中和抗体LY-CoV555)、Baricitinib(巴瑞克替尼,商品名Olumiant)联合Remdesivir、Casirivimab和Imdevimab联合使用(REGN-COV2鸡尾酒疗法)等治疗药物以及Pfizer-BioNTech COVID-19 Vaccine和Moderna COVID-19 Vaccine新冠肺炎疫苗签发了EUA,用于COVID-19的临床治疗...